Related references
Note: Only part of the references are listed.Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit
Wisna Novera et al.
ANTIOXIDANTS & REDOX SIGNALING (2020)
Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
Audrey Debaillon Vesque et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)
Hao Xie et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway
Ge Liu et al.
FASEB JOURNAL (2019)
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Antje Garten et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
Lai Wei et al.
NATURE COMMUNICATIONS (2019)
Role of Mitochondria in Ferroptosis
Minghui Gao et al.
MOLECULAR CELL (2019)
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
Alba Luengo et al.
NATURE COMMUNICATIONS (2019)
FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation
Michael M. Gaschler et al.
NATURE CHEMICAL BIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth
Shiro L. Cramer et al.
NATURE MEDICINE (2017)
ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner
D. Chen et al.
ONCOGENE (2017)
BID links ferroptosis to mitochondrial cell death pathways
Sandra Neitemeier et al.
REDOX BIOLOGY (2017)
ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5
Hui-Lung Sun et al.
CANCER CELL (2016)
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma
Antoine Galmiche et al.
CANCER LETTERS (2014)
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale et al.
NATURE (2014)
PGC-lα mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis
Valerie S. LeBleu et al.
NATURE CELL BIOLOGY (2014)
Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
Ding-Wei Ye et al.
ONCOTARGETS AND THERAPY (2014)
Functions of autophagy in normal and diseased liver
Mark J. Czaja et al.
AUTOPHAGY (2013)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
Christophe Louandre et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib
Wei-feng Mao et al.
ACTA PHARMACOLOGICA SINICA (2012)
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Patrick S. Ward et al.
CANCER CELL (2012)
Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells
Marco Spinazzi et al.
NATURE PROTOCOLS (2012)
Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis
Jianxin Lu et al.
CELL RESEARCH (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Randomized discontinuation trial of sorafenib (BAY 43-9006)
Lokesh Jain et al.
CANCER BIOLOGY & THERAPY (2006)
Share Paper
